IPAR

Publicly Available Assessment Report for a
Veterinary Medicinal Product

FLEANIL 2.5 mg/ml Cutaneous Spray, Solution for Cats and Dogs

PRODUCT SUMMARY

EU Procedure number	IE/V/0324/001/DC
Name, strength and pharmaceutical form	FLEANIL 2.5 mg/ml Cutaneous Spray, Solution for Cats and Dogs
Active substance(s)	Fipronil
Applicant	Norbrook Laboratories (Ireland) Limited Rossmore Industrial Estate Monaghan Ireland
Legal basis of application	Generic application in accordance with Article 13(1) of Directive 2001/82/EC as amended.
Date of completion of procedure	21/05/2014
Target species	Dogs and cats
Indication for use	Treatment of flea (*Ctenocephalides*spp.) and tick (*Ixodes ricinus*, *Rhipicephalus sanguineus*) infestations in dogs and cats. Treatment of biting lice infestations in dogs (*Trichodectes canis*) and cats (*Felicola subrostratus*). Insecticidal efficacy against new infestations with adult fleas persists for up to 2 months in cats and up to 3 months in dogs, depending on environmental challenge. The product has a persistent acaricidal efficacy for up to 4 weeks against ticks, depending on the level of environmental challenge.
ATCvet code	QP53AX15
Concerned Member States	SE

PUBLIC ASSESSMENT REPORT

The public assessment report reflects the scientific conclusion reached by the HPRA at the end of the evaluation process and provides a summary of the grounds for approval of the marketing authorisation for the specific veterinary medicinal product. It is made available by the HPRA for information to the public, after the deletion of commercially confidential information. The legal basis for its creation and availability is contained in Article 25.4 of EC Directive 2001/82/EC as amended by Directive 2004/28/EC for veterinary medicinal products. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the product for marketing in Ireland.

The Summary of Product Characteristics (SPC) for this product is available on the HPRA's website.

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the reactions observed are indicated in the SPC. The product is safe for the user, the consumer of foodstuffs from treated animals and the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall benefit/risk analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Qualitative and Quantitative Particulars

The product contains fipronil 2.5 mg/ml and the excipients copovidone (K28), isopropyl alcohol and purified water. The product is presented in a:
100 ml high density polyethylene bottle fitted with a polypropylene, polyethylene, polyoxymethylene, low-density polyethylene (dip-tube), high density polyethylene and low density polyethylene pump sprayer capable of delivering 0.5 ml per spray.

or

250 ml and 500 ml high density polyethylene bottle fitted with a polypropylene, polyethylene, polyoxymethylene, low-density polyethylene (dip-tube), high density polyethylene and low density polyethylenepump sprayer capable of delivering 1.5 ml per spray.
The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.
Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is fipronil, an established active substance. The active substance is manufactured in accordance with the principles of good manufacturing practice.
The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

D. Control on Intermediate Products

Not applicable.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.
Satisfactory validation data for the analytical methods have been provided.
Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

F. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approvedconditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

G. Other Information

Not applicable.

III SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

This is a 'generic' type application via the decentralised procedure submitted by Norbrook Laboratories Ltd. in accordance with Article 13(1) of Directive 2001/82/EC, as amended. The reference product for this procedure is Frontline Spray (VPA 10857/010/001; Merial Animal Health). Frontline Spray has been authorised in the RMS for greater than 10 years and can be accepted as a valid reference product (originally authorised in 7th July 1995).

It is claimed that the product has the same qualitative and quantitative composition of active ingredient and excipients as the reference veterinary medicinal product, Frontline Spray 0.25% w/v Cutaneous Spray Solution, (i.e. it is claimed to be identical). Both products are solutions and they are used in the same species, for the same indications, in the same doses and using the same administration method.

III.A Safety Testing

Pharmaceutical equivalence between the test and the reference formulation was considered in Part 2. The product has been developed as a generic of Frontline Spray (VPA 10857/010/001; Merial Animal Health) and contains the same quantitative composition of the active substance, fipronil. The pharmaceutical form and dose volumes are also the same as those of the reference product. Selection of several excipients for use in the formulation is based on the fact that information in the public domain identifies them as being present in the reference product: copovidone, purified water and isopropanol. In order to develop a formulation that is identical to the reference product, the applicant undertook a number of tests and investigations to deduce the formulation analytically. Determinations of the components of both the reference and the pioneer products were carried out for two batches of Frontline Spray and two batches of the test product. Specifically the following parameters were tested: fipronil content and related substances, copovidone content, water content, isopropanol content, weight and viscosity.
Based on the information presented it is accepted that the candidate product can be considered identical to the reference product. As such, it is assumed that, for both products, the safety and efficacy profiles will be the same. The omission of bioequivalence studies and the absence of other pharmacological/toxicological studies are justified.

User Safety

A user risk assessment has been provided by the applicant. The risk mitigation measures proposed are in line with those that appear in the SPC of the reference product.
Given that the test product is considered identical to the reference product, it is accepted that the user safety statements agreed for the reference product can be applied to the test product.
The proposed text for section 4.5ii of the SPC can be accepted.

Environmental Risk Assessment

An environmental risk assessment was provided by the applicant. It is concluded that the assessment can end at Phase I. However, the applicant acknowledges that fipronil may be toxic to aquatic organisms. Appropriate risk mitigation measures are included in the SPC.

IV. CLINICAL ASSESSMENT

This is a 'generic' type application via the decentralised procedure submitted by Norbrook Laboratories Ltd. in accordance with Article 13(1) of Directive 2001/82/EC, as amended. The reference product for this procedure is Frontline Spray (VPA 10857/010/001; Merial Animal Health). Frontline Spray has been authorised in the RMS for greater than 10 years and can be accepted as a valid reference product (originally authorised in 7th July 1995).
It is claimed that the product has the same qualitative and quantitative composition of active ingredient and excipients as the reference veterinary medicinal product, Frontline Spray 0.25% w/v Cutaneous Spray Solution, (i.e. it is claimed to be identical). Both products are solutions and they are used in the same species, for the same indications, in the same doses and using the same administration method.

IV.A Pre-Clinical Studies

Pharmacology
See Part III.

Tolerance in the Target Species of Animals

Product specific target animal safety data have not been presented. Given that the test product is considered identical to the reference product, it is accepted that the safety profile of both products will be similar and that the text agreed for sections 4.6 and 4.10 of the authorised reference product can be applied to the test product. The proposed text for sections 4.6 and 4.10 of the SPC can be accepted.

IV.B Clinical Studies

Given that the test product is considered identical to the reference product, and that the conditions of use will be the same, it is accepted that the efficacy profile of both products will be similar. The proposed indications for use and posology are generally in line with those agreed for the reference product and can be accepted.

V. OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the benefit/risk profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

VI. POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the HPRA website.

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

Changes:

None.